Jasper Therapeutics, Inc. Common Stock
JSPRStock
$0.77−79.09%52W
Market Cap$21.57M
P/E—
Div yield—
Beta3.13
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-75.70%
Price vs S&P 500 (4W)52.40%
VGM Score34.10
Market Capitalization$21.57M
Earnings Surprise History
Q1 26-0.04est. -0.50
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
3.93
3.93
3.86
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JSPRJasper Therapeutics, Inc. Common Stock | — | — | D | $0.77 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Jasper Therapeutics is a clinical-stage biotechnology company developing treatments based on hematopoietic stem cell transplantation. The company is developing safer conditioning agents and advanced stem cell engineering technologies to expand the therapeutic applications of stem cell transplantation and ex vivo gene therapy. By improving the safety and efficacy of these procedures, Jasper aims to enable broader patient access to stem cell-based treatments across multiple disease indications.